50 research outputs found
Imaging in population science: cardiovascular magnetic resonance in 100,000 participants of UK Biobank - rationale, challenges and approaches
PMCID: PMC3668194SEP was directly funded by the National Institute for Health Research
Cardiovascular Biomedical Research Unit at Barts. SN acknowledges support
from the Oxford NIHR Biomedical Research Centre and from the Oxford
British Heart Foundation Centre of Research Excellence. SP and PL are
funded by a BHF Senior Clinical Research fellowship. RC is supported by a
BHF Research Chair and acknowledges the support of the Oxford BHF Centre
for Research Excellence and the MRC and Wellcome Trust. PMM gratefully
acknowledges training fellowships supporting his laboratory from the
Wellcome Trust, GlaxoSmithKline and the Medical Research Council
Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis
The ADA and the EASD recently published a consensus statement for the medical management of hyperglycaemia in patients with type 2 diabetes. The authors advocate initial treatment with metformin monotherapy and lifestyle modification, followed by addition of basal insulin or a sulfonylurea if glycaemic goals are not met (tier 1 recommendations). All other glucose-lowering therapies are relegated to a secondary (tier 2) status and only recommended for selected clinical settings. In our view, this algorithm does not offer physicians and patients the appropriate selection of options to individualise and optimise care with a view to sustained control of blood glucose and reduction both of diabetes complications and cardiovascular risk. This paper critically assesses the basis of the ADA/EASD algorithm and the resulting tiers of treatment options
Quantitative Coronary Dimensions and Restenosis After Directional Atherectomy or Balloon Angioplasty
Recent HbA1c values and mortality risk in type 2 diabetes. population-based case-control study.
This study aimed to evaluate mortality within 365 days of HbA1c values of 9.0% in participants with clinical type 2 diabetes mellitus. A matched nested case-control study was implemented, within a cohort of participants with type 2 diabetes from 2000 to 2008. Conditional logistic regression was used to model the odds ratio for mortality adjusting for comorbidity and drug utilisation. There were 97,450 participants with type 2 diabetes; 16,585 cases that died during follow up were matched to 16,585 controls. The most recent HbA1c value was 9.0% for 9.0% of cases and 7.7% of controls. In a complete case analysis, the adjusted odds ratio (AOR) for mortality associated with most recent HbA1c 9.0% of 1.51 (CI: 1.33, 1.70), in the multiple imputation analysis this was 1.29 (1.17,1.41). The risk associated with HbA1c 9.0% may be associated with increased mortality within one year in clinical type 2 diabetes. Relative risks may be higher at younger ages